Maseco LLP bought a new position in Astrazeneca Plc (NYSE:AZN – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 7,410 shares of the company’s stock, valued at approximately $1,441,000.
Several other hedge funds have also recently made changes to their positions in the company. MV Capital Management Inc. purchased a new stake in Astrazeneca in the 4th quarter worth about $26,000. Reflection Asset Management bought a new stake in Astrazeneca in the 4th quarter valued at about $31,000. Lloyd Advisory Services LLC. purchased a new stake in Astrazeneca during the fourth quarter valued at about $35,000. Basepoint Wealth LLC purchased a new stake in Astrazeneca during the fourth quarter valued at about $44,000. Finally, Acumen Wealth Advisors LLC bought a new position in Astrazeneca during the fourth quarter worth about $47,000. 20.35% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Finally, Weiss Ratings lowered Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $205.33.
Astrazeneca Trading Up 1.4%
Shares of Astrazeneca stock opened at $185.61 on Friday. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71. The firm has a market cap of $287.86 billion, a PE ratio of 27.87, a PEG ratio of 1.59 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The company has a 50 day simple moving average of $184.90 and a two-hundred day simple moving average of $186.80.
Astrazeneca (NYSE:AZN – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Analysts expect that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Stories
- Five stocks we like better than Astrazeneca
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
